课题基金 / 基金详情

A BIOMARKER AND PHASE II STUDY OF GW 572016 IN RECURRENT MALIGNANT GLIOMA (NA

A BIOMARKER AND PHASE II STUDY OF GW 572016 IN RECURRENT MALIGNANT GLIOMA (NA
GW 572016 在复发性恶性胶质瘤中的生物标志物和 II 期研究（NA）
批准号：
7717990
负责人：
TIMOTHY CLOUGHESY
金额：
$0.14万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-12-01 至 2008-11-30
来源：
https://reporter.nih.gov/project-details/7717990
关键词：
Biological MarkersComputer Retrieval of Information on Scientific Projects DatabaseERBB2 geneEpidermal Growth Factor ReceptorFundingGW572016GlioblastomaGrantInstitutionMalignant GliomaPatientsPhase II Clinical TrialsPhosphorylationProgression-Free SurvivalsRecurrenceResearchResearch PersonnelResourcesSignal PathwaySourceSurvival RateUnited States National Institutes of Healthcellular targetingin vivotumor

项目摘要

项目成果

TIMOTHY CLOUGHESY的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary aims: ¿ Determine the 6-month progression-free survival rate for patients with recurrent or progressive glioblastoma treated with GW572016. ¿ Determine whether GW572016 inhibits the phosphorylation of its cellular targets EGFR and HER2, and the downstream PI3K-AKT and RAS-ERK signaling pathways in glioblastoma patients in vivo. ¿ Determine tumor concentrations of GW572016. Secondary aims: ¿ Overall progression free survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
Career Enhancement Program
Career Enhancement Program